Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

NCT05412004 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults who have both obstructive sleep apnea and obesity to see how it affects their breathing during sleep.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 469 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-06 · est. completion 2024-03

Where 58 sites · Australia, Brazil, China, Czechia, Germany, Japan, Mexico, Puerto Rico, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT05412004 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline in Apnea-Hypopnea Index (AHI)
Sponsor	Eli Lilly and Company
Conditions studied	Obstructive Sleep Apnea, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05412004 ↗